NCT05267366

Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC

Phase II Randomized Trial of Carboplatin/Cisplatin+Pemetrexed+PD-1 Inhibitor+/- Bevacizumab in Stage IV Non-squamous NSCLC

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 117 (estimated)
• Sponsor: Qingdao Central Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

In recent years, immunotherapy has emerged as a form of treatment that can lead to robust responses in a subset of patients. PD-1 inhibitor plus chemotherapy showed prolonged survival in NSCLC by the study of KEYNOTE 024, KEYNOTE 189 etc. Thus, this study combines immunotherapeutic agent PD-1 inhibitor with an ant-angiogenic agent, bevacizumab, and double platinum therapy (carboplatin/cisplatin and pemetrexed).

Conditions

• PFS
• OS

Interventions

Type	Name	Description
DRUG	PD-1 inhibitor, Bevacizumab, Carboplatin, Cisplatin, Pemtrexed	PD-1 inhibitor (pembrolizumab) 200mg iv, d1; bevzcizumab 15mg/kg, iv, d1; Carboplatin 5/AUC or Cisplatin 75mg/m2 iv d1; Pemtrexed 500mg/m2 iv, d1; every 21 days a cycle.

Timeline

• Start date: 2022-02-01
• Primary completion: 2024-02-01
• Completion: 2024-07-01
• First posted: 2022-03-04
• Last updated: 2023-03-29

Locations

1 site across 1 country: China